Immuno-biological Laboratories Co., Ltd.

Kyoto University

Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology

Tsutomu Seito

Hiroko Kobayashi

Masahiro Hasegawa

Takahiko Shimizu

Yuichi Masuda

Takuji Shirasawa

Kazuhiro Irie

Kazuma Murakami

Provided is a therapeutic method exclusively targeting an amyloid &#x3b2; protein (A&#x3b2;) having a specific turn structure of A&#x3b2;. Specifically provided is an antibody which specifically recognizes an amyloid &#x3b2; having a turn structure at amino acids positions 22 and 23. Also provided are a medicinal composition comprising, as the active ingredient, an antibody specifically recognizing a toxic conformer of amyloid &#x3b2;, an assay kit for a toxic conformer of amyloid &#x3b2;, a diagnostic for Alzheimer's disease, etc.

Antibody recognizing turn structure in amyloid &#x3b2;

The purpose of the invention is to provide an antibody which recognizes OPN N-half but does not recognize the full-length OPN, and its use. A monoclonal antibody which is characterized in that it recognizes a protein or polypeptide in which the C-terminal amino acid sequence is YGLR (SEQ ID NO: 1) and it substantially does not recognize a protein or polypeptide which has an amino acid sequence of YGLR outside of the C-terminal, as well as a method for measuring OPN N-half utilizing the said antibody, a method for diagnosing diseases relating to OPN N-half, a method for judging the severity of said disease, and a method for treating said diseases, are provided.

Monoclonal antibody and use thereof

Growing community of inventors

Takasaki, Japan

Tsutomu Seito